Dogs: SENERGY kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea infestations (Ctenocephalides felis)， prevention of heartworm disease caused by Dirofilaria immitis， and the treatment and control of ear mite (Otodectes cynotis) infestations. SENERGY also is indicated for the treatment and control of sarcoptic mange (Sarcoptes scabiei) and for the control of tick infestations due to Dermacentor variabilis. Cats:SENERGY kills adult fleas and prevents flea eggs from hatchingfor one month and is indicated for the prevention and control offlea infestations (Ctenocephalides felis)， prevention of heartwormdisease caused by Dirofilaria immitis， and the treatment andcontrol of ear mite (Otodectes cynotis) infestations. SENERGYis also indicated for the treatment and control of roundworms(Toxocara cati) and intestinal hookworm (Ancylostomatubaeforme) infections in cats.

PRECAUTIONS: Prior to administration of SENERGY， dogs should be tested for existing heartworm infections. At the discretion of the veterinarian， infected dogs should be treated to remove adult heartworms. Selamectin is not effective against adult D. immitis and， while the number of circulating microfilariae may decrease following treatment， selamectin is not effective for microfilariae clearance. Hypersensitivity reactions have not been observed in dogs with patent heartworm infections administered three times the recommended dose of selamectin. Higher doses were not tested. ADVERSE REACTIONS: Pre-approval clinical trials: Following treatment with selamectin， transient localized alopecia with or without inflammation at or near the site of application was observed in approximately 1% of 691 treated cats. Other signs observed rarely (?0.5% of 1743 treated cats and dogs) included vomiting， loose stool or diarrhea with or without blood， anorexia， lethargy， salivation， tachypnea， and muscle tremors. Post-approval experience: In addition to the aforementioned clinical signs that were reported in pre-approval clinical trials， there have been reports of pruritus， urticaria， erythema， ataxia， fever， and rare reports of death. There have also been rare reports of seizures in dogs.

No food and drug interactions have been reported.

WARNINGS: Not for human use. Keep out of the reach of children. In humans， SENERGY may be irritating to skin and eyes. Reactions such as hives， itching and skin redness have been reported in humans in rare instances. Individuals with known hypersensitivity to SENERGY should use the product with caution or consult a health care professional. SENERGY contains isopropyl alcohol and the preservative butylated hydroxytoluene (BHT). Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If contact with eyes occurs， then flush eyes copiously with water. In case of ingestion by a human， contact a physician immediately. The safety data sheet (SDS) provides more detailed occupational safety information. To report suspected adverse drug events， for technical assistance or to obtain a copy of the SDS， contact Virbac AH， Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs， contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae. Flammable - Keep away from heat， sparks， open flames or other sources of ignition. Do not use in sick， debilitated or underweight animals (see SAFETY). PRECAUTIONS: Prior to administration of SENERGY， dogs should be tested for existing heartworm infections. At the discretion of the veterinarian， infected dogs should be treated to remove adult heartworms. Selamectin is not effective against adult D. immitis and， while the number of circulating microfilariae may decrease following treatment， selamectin is not effective for microfilariae clearance. Hypersensitivity reactions have not been observed in dogs with patent heartworm infections administered three times the recommended dose of selamectin. Higher doses were not tested.